Alaunos Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Alaunos Therapeutics
TCRT Stock  USD 2.95  0.13  4.22%   
Analyzing historical trends in various income statement and balance sheet accounts from Alaunos Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alaunos Therapeutics' valuation are summarized below:
Gross Profit
-910 K
Market Capitalization
6.9 M
Enterprise Value Revenue
135.3388
Revenue
6 K
Earnings Share
(2.30)
There are currently one hundred twenty fundamental signals for Alaunos Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Alaunos Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 3.3 M in 2026. Enterprise Value is likely to drop to about 2.1 M in 2026

Alaunos Therapeutics Total Revenue

8,550

Check Alaunos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alaunos Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.2 K, Selling And Marketing Expenses of 4.1 M or Total Revenue of 8.6 K, as well as many indicators such as Price To Sales Ratio of 261, Dividend Yield of 0.0294 or PTB Ratio of 1.4. Alaunos financial statements analysis is a perfect complement when working with Alaunos Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Alaunos Stock
Check out the analysis of Alaunos Therapeutics Correlation against competitors.
For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.

Alaunos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3 M3.2 M70.7 M
Slightly volatile
Short and Long Term Debt Total12.6 M23.1 M8.9 M
Slightly volatile
Cash1.2 M1.3 M56.6 M
Slightly volatile
Other Assets0.860.96.3 M
Slightly volatile
Cash And Short Term Investments1.2 M1.3 M56.6 M
Slightly volatile
Net Receivables5.5 K5.8 K700.3 K
Pretty Stable
Common Stock Shares Outstanding1.9 M1.8 M1.1 M
Slightly volatile
Liabilities And Stockholders Equity3 M3.2 M70.7 M
Slightly volatile
Other Current Assets1.8 M1.9 M10.4 M
Very volatile
Other Stockholder Equity1.1 B1.1 B666 M
Slightly volatile
Total Liabilities756 K795.8 K39.5 M
Pretty Stable
Total Current Assets3 M3.2 M65.8 M
Slightly volatile
Intangible Assets582437517
Slightly volatile
Other Current Liabilities192.3 K202.4 K6.7 M
Slightly volatile
Total Current Liabilities756 K795.8 K11.2 M
Slightly volatile
Accounts Payable563.7 K593.4 K1.2 M
Pretty Stable
Common Stock2.2 K2.3 K112.9 K
Pretty Stable
Short Term Investments1.2 M1.4 M1.5 M
Slightly volatile
Current Deferred Revenue14.2 K14.9 K1.4 M
Slightly volatile
Property Plant Equipment8.1 M9.7 M5.2 M
Slightly volatile
Net Invested Capital1.8 M1.9 M67 M
Slightly volatile
Capital Stock1.7 K1.8 K136.7 K
Slightly volatile
Net Working Capital1.8 M1.9 M57.8 M
Slightly volatile
Property Plant And Equipment Gross12.8 K13.5 K7.8 M
Slightly volatile
Short Term Debt21.6 M20.6 M6.7 M
Slightly volatile
Long Term Debt13 M14.6 M16 M
Slightly volatile
Short and Long Term Debt13.5 M19.3 M10.4 M
Slightly volatile
Common Stock Total Equity192 K216 K235.8 K
Slightly volatile
Capital Surpluse735.2 M827 M902.7 M
Slightly volatile
Inventory11.2 M12.5 M13.7 M
Slightly volatile

Alaunos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.2 K2.3 K773.5 K
Slightly volatile
Selling And Marketing Expenses4.1 M2.7 M2.3 M
Slightly volatile
Other Operating Expenses5.3 M5.5 M58.4 M
Slightly volatile
Total Operating Expenses5.3 M5.5 M58.1 M
Slightly volatile
Research Development395.5 K416.3 K44 M
Slightly volatile
Selling General Administrative4.9 M5.1 M14.8 M
Pretty Stable
Reconciled Depreciation2.2 K2.3 K886 K
Pretty Stable
Cost Of Revenue5.8 M5.5 M1.9 M
Slightly volatile
Non Operating Income Net Other423.2 K476.1 K519.7 K
Slightly volatile

Alaunos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow6.6 M7 M61.6 M
Slightly volatile
Depreciation2.2 K2.3 K773.7 K
Slightly volatile
End Period Cash Flow1.2 M1.3 M57.5 M
Slightly volatile
Stock Based Compensation475.2 K500.2 K4.8 M
Pretty Stable
Dividends Paid13.3 M19.5 M12.9 M
Slightly volatile
Change To Netincome6 K6.3 K10.1 M
Pretty Stable
Change Receivables885.6 K996.3 K1.1 M
Slightly volatile
Cash Flows Other Operating3.4 M3.9 M4.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio261275710
Very volatile
Dividend Yield0.02940.0570.0391
Slightly volatile
Days Sales Outstanding110164296
Pretty Stable
Average Payables465.9 K725.5 K755 K
Very volatile
Stock Based Compensation To Revenue41.1139.1519.2878
Slightly volatile
Capex To Depreciation0.07280.07661.4307
Pretty Stable
EV To Sales215226557
Pretty Stable
Payables Turnover7.377.023.1586
Slightly volatile
Sales General And Administrative To Revenue2.3 K2.2 K579
Slightly volatile
Research And Ddevelopement To Revenue30.9532.58258
Pretty Stable
Capex To Revenue37.2335.4610.8327
Slightly volatile
Cash Per Share0.740.7870.8414
Slightly volatile
Days Payables Outstanding51.1453.83345
Slightly volatile
Income Quality0.580.960.7298
Pretty Stable
Intangibles To Total Assets0.520.870.9004
Very volatile
Current Ratio4.823.585.4623
Pretty Stable
Receivables Turnover690657250
Slightly volatile
Capex Per Share0.130.141.1169
Pretty Stable
Average Receivables186209228
Slightly volatile
Revenue Per Share0.00680.00721.8079
Slightly volatile
Interest Debt Per Share1.311.383.5713
Pretty Stable
Debt To Assets0.570.360.2534
Very volatile
Operating Cycle110164296
Pretty Stable
Days Of Payables Outstanding51.1453.83345
Slightly volatile
Ebt Per Ebit0.820.881.0182
Very volatile
Quick Ratio4.813.585.4278
Pretty Stable
Cash Ratio1.721.814.3781
Slightly volatile
Days Of Sales Outstanding110164296
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.860.913.4317
Pretty Stable
Fixed Asset Turnover2.842.882.1901
Very volatile
Debt Ratio0.570.360.2534
Very volatile
Price Sales Ratio261275710
Very volatile
Asset Turnover0.0040.00420.0518
Slightly volatile

Alaunos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 M3.5 M355.7 M
Slightly volatile
Enterprise Value2.1 M2.3 M298 M
Slightly volatile

Alaunos Fundamental Market Drivers

Alaunos Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alaunos Therapeutics Financial Statements

Alaunos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Alaunos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Alaunos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Alaunos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14.9 K14.2 K
Total Revenue9 K8.6 K
Cost Of Revenue5.5 M5.8 M
Stock Based Compensation To Revenue 39.15  41.11 
Sales General And Administrative To Revenue2.2 K2.3 K
Research And Ddevelopement To Revenue 32.58  30.95 
Capex To Revenue 35.46  37.23 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(553.38)(581.05)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alaunos Stock Analysis

When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY